The most troublesome complication of acute pericarditis is recurrent pericardial inflammation, which occurs in 15%32% of cases. The optimal method for prevention has not been fully established; accepted modalities include nonsteroidal anti-inflammatory drugs, corticosteroids, immunosuppressive agents, and pericardiectomy. Over the last years, objective clinical evidence has matured and clearly indicates the important role and beneficial clinical effect of colchicine therapy in preventing recurrent pericarditis caused by various etiologies. Colchicine-treated patients consistently display significantly fewer recurrences and longer symptom-free periods, and even when attacks occur, they are weaker and shorter in nature. Notably, pretreatment with corticosteroids substantially attenuates the efficacy of colchicine, causing significantly more recurrences and longer therapy periods. The safety profile seems superior to other drugs, such as corticosteroids and immunosuppressive drugs. Colchicine is a safe and effective modality for the treatment and prevention of recurrent pericarditis, especially as an adjunct to other modalities, because it provides a sustained benefit, superior to all current modalities. The authors have no funding, financial relationships, or conflicts of interest to disclose.
Prevention of recurrent pericarditis with colchicine in 2012 / G. Markel, M. Imazio, A. Brucato, Y. Adler. - In: CLINICAL CARDIOLOGY. - ISSN 1932-8737. - 36:3(2013), pp. 125-128.
|Titolo:||Prevention of recurrent pericarditis with colchicine in 2012|
|Parole Chiave:||Postpericardiotomy-syndrome; syndrome copps; therapy; management; trial; multicenter|
|Settore Scientifico Disciplinare:||Settore MED/09 - Medicina Interna|
|Data di pubblicazione:||2013|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1002/clc.22098|
|Appare nelle tipologie:||01 - Articolo su periodico|